3-iodo-5-methylaniline | 74586-54-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-iodo-5-methylaniline
• 英文别名: 3-Jod-5-methyl-anilin；5-Jod-3-amino-toluol；3-iodo-5-methyl-benzenamine
• CAS: 74586-54-2
• 化学式: C₇H₈IN
• mdl: MFCD12965021
• 分子量: 233.052
• InChiKey: LOUHGQOWBDORSI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-iodo-5-methylaniline 在 三氯氧磷 、 三甲基乙酸 作用下， 反应 1.0h， 生成 4-chloro-N-(3-iodo-5-methylphenyl)pyrimidin-2-amine
  参考文献：
  名称：

  SNAr Reactions of 2-Methylthio-4-pyrimidinones in Pivalic Acid: Access to Functionalized Pyrimidinones and Pyrimidines

  摘要：

  皮伐酸是一种有效的介质，可以直接实现2-甲硫基-4-吡啶酮与多种芳香胺的SNAr置换反应。产物易于分离，收益良好至优秀，随后进行氯化，可以为快速探究功能化吡啶的4位结构-活性关系提供机会。

  DOI：

  10.1055/s-0031-1289744
• 作为产物：
  描述：

  3,5-二硝基甲苯 在 盐酸 、 ammonium polysulphide 、 potassium iodide 、 tin(ll) chloride 作用下， 生成 3-iodo-5-methylaniline
  参考文献：
  名称：

  氯化吡咯与一些取代的苯胺反应的动力学。第5部分

  摘要：

  已测量了氯化吡咯与以下取代的苯胺在乙腈中的反应的Arrhenius参数：3-氨基和3-甲基苯胺，3-氨基-5-硝基苯胺，3-氟-5-甲基磺酰基苯胺，3- X-5-甲基苯胺（X = NO 2，OMe，CH 3，F，Cl，Br或I）和3,5-X 2-苯胺（X = F，Cl，Br或I）。现已研究了总共33个3,5-二取代苯胺对取代基对活化自由能的可加性的影响，并且表明，除3-氨基-5-硝基苯胺外，该假说重现了实验速率常数。在2分之一的范围内，当使用更严格的可加性标准时，对于某些情况下出现的偏差提出了合理化建议。

  DOI：

  10.1039/p29800000829

文献信息

• [EN] IMIDAZOLYL ANALOGS AS SYK INHIBITORS<br/>[FR] ANALOGUES D'IMIDAZOLYLE EN TANT QU'INHIBITEURS DE SYK
  申请人：MERCK SHARP & DOHME

  公开号：WO2013192128A1

  公开（公告）日：2013-12-27

  The present invention provides novel imidazole analogs of Formula I which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD, rheumatoid arthritis, and cancer.

  本发明提供了一种新型的咪唑类似物，其化学式为I，这些类似物是脾酪氨酸激酶的有效抑制剂，可用于治疗和预防由该酶介导的疾病，如哮喘、慢性阻塞性肺疾病、类风湿性关节炎和癌症。
• Kynurenic acid derivatives useful in the treatment of neurodegenerative
  申请人：Merck Sharp & Dohme Limited

  公开号：US05270309A1

  公开（公告）日：1993-12-14

  4-Oxo-1,4-dihydroquinoline compounds having a 2-acidic group or a group convertible thereto in vivo, and their pharmaceutically acceptable salts, are potent specific antagonists of N-methyl-D-aspartate (NMDA) receptors and are therefore useful in the treatment of neurodegenerative disorders. 4-Oxo-1,4-dihydroquinoline compounds having a 2-acidic group or a group convertible thereto in vivo, other than carboxy or C.sub.1-6 alkoxycarbonyl, are novel compounds, as also are compounds of formula II ##STR1## wherein R.sup.2 represents carboxy or a group convertible thereto in vivo, R.sup.6 is hydrogen and R.sup.5 and R.sup.7 represent C.sub.1-6 alkyl or halogen, provided that R.sup.5 and R.sup.7 are not simultaneously chlorine or simultaneously bromine; a process for preparing the novel compounds is described, as also are pharmaceutical compositions containing the novel compounds.

  具有2-酸性基团或可在体内转化为该基团的4-氧代-1,4-二氢喹啉化合物及其药用可接受的盐是N-甲基-D-天冬氨酸（NMDA）受体的有效特异性拮抗剂，因此在治疗神经退行性疾病方面具有用途。具有2-酸性基团或可在体内转化为该基团的4-氧代-1,4-二氢喹啉化合物，除了羧基或C.sub.1-6烷氧羰基之外，是新颖的化合物，公式II的化合物也是新颖的，其中R.sup.2代表羧基或可在体内转化为该基团的基团，R.sup.6为氢，R.sup.5和R.sup.7代表C.sub.1-6烷基或卤素，但要求R.sup.5和R.sup.7不能同时是氯或溴；描述了制备这些新颖化合物的方法，以及含有这些新颖化合物的药物组合物。
• IMIDAZOLYL ANALOGS AS SYK INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20150175575A1

  公开（公告）日：2015-06-25

  The present invention provides novel imidazole analogs of Formula I which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD, rheumatoid arthritis, and cancer.

  本发明提供了一种新型咪唑类似物I的化合物，它们是脾酪氨酸激酶的有效抑制剂，可用于治疗和预防由该酶介导的疾病，如哮喘、COPD、类风湿性关节炎和癌症。
• Kynurenic acid derivatives useful in the treatment of neurodegenerative disorders
  申请人：MERCK SHARP & DOHME LTD.

  公开号：EP0303387A1

  公开（公告）日：1989-02-15

  4-Oxo-1,4-dihydroquinoline compounds having a 2-acidic group or a group convertible thereto in vivo, and their pharmaceutically acceptable salts, are potent specific antagonists of N-methyl-D-­aspartate (NMDA) receptors and are therefore useful in the treatment of neurodegenerative disorders. 4-Oxo-1,4-dihydroquinoline compounds having a 2-­acidic group or a group convertible thereto in vivo, other than carboxy or C₁₋₆ alkoxycarbonyl, are novel compounds, as also are compounds of formula II wherein R² represents carboxy or a group convertible thereto in vivo, R⁶ is hydrogen and R⁵ and R⁷ represent C₁₋₆ alkyl or halogen, provided that R⁵ and R⁷ are not simultaneously chlorine or simultaneously bromine; a process for preparing the novel compounds is described, as also are pharmaceutical compositions containing the novel compounds.

  具有 2-酸性基团或体内可转化基团的 4-氧代-1,4-二氢喹啉化合物及其药学上可接受的盐类是 N-甲基-D-天冬氨酸（NMDA）受体的强效特异性拮抗剂，因此可用于治疗神经退行性疾病。除羧基或 C₁₋₆ 烷氧羰基外，具有 2-酸性基团或在体内可转化的基团的 4-氧代-1,4-二氢喹啉化合物是新型化合物，如式 II 所示的化合物 其中 R² 代表羧基或体内可转化为羧基的基团，R⁶ 是氢，R⁵ 和 R⁷ 代表 C₁₋₆ 烷基或卤素，但 R⁵ 和 R⁷ 不能同时为氯或同时为溴。
• METHOD FOR PREPARING ACETIC ACID BY CARBONYLATION OF METHANOL
  申请人：Dalian Institute of Chemical Physics, Chinese Academy of Sciences

  公开号：EP3330248A1

  公开（公告）日：2018-06-06

  The present invention provides a method for preparing acetic acid by carbonylation of methanol, which comprises: passing a raw material containing methanol, carbon monoxide and water through a reaction region loaded with a catalyst containing an acidic molecular sieve with an adsorbed organic amine, and carrying out a reaction under the following conditions to prepare acetic acid. The method in the present invention offers high acetic acid selectivity and good catalyst stability. The catalyst in the present invention does not contain noble metals such as rhodium or iridium, and does not need additional agent containing iodine, and thus does not generate a strong corrosive hydroiodic acid and the like.

  本发明提供了一种通过甲醇羰基化制备乙酸的方法，该方法包括：将含有甲醇、一氧化碳和水的原料通过装载有吸附有机胺的酸性分子筛催化剂的反应区，并在以下条件下进行反应以制备乙酸。本发明的方法具有较高的乙酸选择性和良好的催化剂稳定性。本发明的催化剂不含铑或铱等贵金属，也不需要额外的含碘剂，因此不会产生强腐蚀性的氢碘酸等。